Comprehensive clinical and molecular studies in split-hand/foot malformation: identification of two plausible candidate genes (LRP6 and UBA2).


Journal

European journal of human genetics : EJHG
ISSN: 1476-5438
Titre abrégé: Eur J Hum Genet
Pays: England
ID NLM: 9302235

Informations de publication

Date de publication:
12 2019
Historique:
received: 07 03 2019
accepted: 02 07 2019
revised: 27 05 2019
pubmed: 25 7 2019
medline: 18 7 2020
entrez: 24 7 2019
Statut: ppublish

Résumé

Split-hand/foot malformation (SHFM) is a clinically and genetically heterogeneous condition. We sequentially performed screening of the previously identified Japanese founder 17p13.3 duplication/triplication involving BHLHA9, array comparative genomic hybridization, and whole exome sequencing (WES) in newly recruited 41 Japanese families with non-syndromic and syndromic SHFM. We also carried out WES in seven families with nonsyndromic and syndromic SHFM in which underlying genetic causes including pathogenic copy-number variants (CNVs) remained undetected in our previous studies of 56 families. Consequently, we identified not only known pathogenic CNVs (17p13.3 duplications/triplications [n = 21], 2q31 deletion [n = 1], and 10q24 duplications [n = 3]) and rare variants in known causative genes (TP63 [n = 3], DLX5 [n = 1], IGF2 [n = 1], WNT10B [n = 3], WNT10B/PORCN [n = 1], and PORCN [n = 1]), but also a de novo 19q13.11 deletion disrupting UBA2 (n = 1) and variants that probably affect function in LRP6 (n = 1) and UBA2 (n = 1). Thus, together with our previous data based on testing of 56 families, molecular studies for a total of 97 families with SHFM revealed underlying genetic causes in 75 families, and clinical studies for the 75 families indicated a certain degree of correlation between genetic causes and phenotypes. The results imply that SHFM primarily occurs as a genetic disorder with genotype-phenotype correlations. Furthermore, the results together with previous data such as the development of SHFM in Lrp6 knockout mice, the presence of SHFM in two subjects with 19q13 deletions involving UBA2, and strong mouse Uba2 expression in the developing limb buds, imply that LRP6 and UBA2 represent plausible candidate genes for SHFM.

Identifiants

pubmed: 31332306
doi: 10.1038/s41431-019-0473-7
pii: 10.1038/s41431-019-0473-7
pmc: PMC6871171
doi:

Substances chimiques

LRP6 protein, human 0
Low Density Lipoprotein Receptor-Related Protein-6 0
UBA2 protein, human 0
Ubiquitin-Activating Enzymes EC 6.2.1.45

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1845-1857

Références

PLoS One. 2011;6(9):e24812
pubmed: 21931855
Am J Med Genet A. 2015 Dec;167A(12):3226-8
pubmed: 26333411
Acta Histochem. 2018 Apr;120(3):205-214
pubmed: 29409666
Curr Opin Genet Dev. 2007 Aug;17(4):359-66
pubmed: 17644373
Am J Med Genet C Semin Med Genet. 2016 Mar;172C(1):9-20
pubmed: 26853229
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
Nature. 2000 Mar 30;404(6777):455-6
pubmed: 10761903
Gene. 2018 Mar 1;645:34-40
pubmed: 29246538
Eur J Hum Genet. 2014 Sep;22(9):1105-10
pubmed: 24496061
Trends Mol Med. 2006 Jul;12(7):306-16
pubmed: 16782405
Am J Med Genet A. 2013 Nov;161A(11):2860-72
pubmed: 24115638
Mol Cytogenet. 2014 Dec 12;7(1):61
pubmed: 25516771
Hum Mutat. 2017 May;38(5):503-506
pubmed: 28087897
Orphanet J Rare Dis. 2014 Oct 21;9:125
pubmed: 25351291
J Med Genet. 2012 Feb;49(2):119-25
pubmed: 22147889
J Hum Genet. 2017 Oct;62(10):877-884
pubmed: 28539665
J Med Genet. 2011 Feb;48(2):98-104
pubmed: 21068127
Cell Cycle. 2005 Jan;4(1):183-90
pubmed: 15611636
Mol Cytogenet. 2015 Mar 26;8:21
pubmed: 25883683
Am J Med Genet A. 2014 Jan;164A(1):62-9
pubmed: 24243649
Dev Cell. 2013 Mar 11;24(5):530-42
pubmed: 23453598
Development. 2004 Mar;131(5):1187-94
pubmed: 14973274
Nature. 2016 Aug 17;536(7616):285-91
pubmed: 27535533
Clin Case Rep. 2018 May 28;6(7):1300-1307
pubmed: 29988626
Nature. 2000 Sep 28;407(6803):535-8
pubmed: 11029008
Am J Hum Genet. 2002 Jul;71(1):1-13
pubmed: 12037717
Development. 2011 Jan;138(2):203-13
pubmed: 21148188
Cell. 1999 Oct 15;99(2):143-53
pubmed: 10535733
Nat Genet. 1997 Feb;15(2):179-80
pubmed: 9020844
Am J Hum Genet. 2015 Oct 1;97(4):621-6
pubmed: 26387593
BMC Genomics. 2011 Apr 12;12:184
pubmed: 21486468
Orphanet J Rare Dis. 2010 Jun 23;5:19
pubmed: 20573229
Microarrays (Basel). 2015 Dec 24;5(1):
pubmed: 27600068
Hum Mol Genet. 2014 Apr 1;23(7):1687-99
pubmed: 24203697
Hum Mutat. 2017 Aug;38(8):953-958
pubmed: 28489339
Genet Med. 2016 Nov;18(11):1158-1162
pubmed: 26963285
Hum Genet. 2018 Jan;137(1):95-104
pubmed: 29322246
Hum Mutat. 2018 Jun;39(6):811-815
pubmed: 29524275
N Engl J Med. 2015 Jul 23;373(4):349-56
pubmed: 26154720
Am J Med Genet A. 2017 Mar;173(3):758-761
pubmed: 28110515

Auteurs

Kaori Yamoto (K)

Department of Pediatrics, Hamamatsu University School of Medicine, Hamamatsu, Japan.

Hirotomo Saitsu (H)

Department of Biochemistry, Hamamatsu University School of Medicine, Hamamatsu, Japan.

Gen Nishimura (G)

Center for Intractable Diseases, Saitama Medical University Hospital, Iruma, Japan.

Rika Kosaki (R)

Division of Medical Genetics, National Center for Child Health and Development, Tokyo, Japan.

Shinichiro Takayama (S)

Division of Orthopedic Surgery, National Center for Child Health and Development, Tokyo, Japan.

Nobuhiko Haga (N)

Department of Rehabilitation Medicine, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.

Hidefumi Tonoki (H)

Department of Pediatrics, Sapporo Tenshi Hospital, Sapporo, Japan.

Akihisa Okumura (A)

Department of Pediatrics, Aichi Medical University, Nagakute, Japan.

Emiko Horii (E)

Department of Orthopedic Surgery, Nagoya First Red Cross Hospital, Nagoya, Japan.

Nobuhiko Okamoto (N)

Department of Medical Genetics, Osaka Women's and Children's Hospital, Osaka, Japan.

Hiroshi Suzumura (H)

Department of Pediatrics, Dokkyo Medical University School of Medicine, Mibu, Japan.

Shiro Ikegawa (S)

Laboratory of Bone and Joint Diseases, Center for Integrative Medical Sciences, RIKEN, Tokyo, Japan.

Fumiko Kato (F)

Department of Pediatrics, Hamamatsu University School of Medicine, Hamamatsu, Japan.

Yasuko Fujisawa (Y)

Department of Pediatrics, Hamamatsu University School of Medicine, Hamamatsu, Japan.

Eiko Nagata (E)

Department of Pediatrics, Hamamatsu University School of Medicine, Hamamatsu, Japan.

Shuji Takada (S)

Department of Systems BioMedicine, National Research Institute for Child Health and Development, Tokyo, Japan.

Maki Fukami (M)

Department of Molecular Endocrinology, National Research Institute for Child Health and Development, Tokyo, Japan.

Tsutomu Ogata (T)

Department of Pediatrics, Hamamatsu University School of Medicine, Hamamatsu, Japan. tomogata@hama-med.ac.jp.
Department of Molecular Endocrinology, National Research Institute for Child Health and Development, Tokyo, Japan. tomogata@hama-med.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH